drugset / Trial / NCT00559286
Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels
Phase 4
Terminated
40 enrolled
RWTH Aachen University
Bayer · collabCTCA · collabHeidelberg University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The hypothesis of the presented study is: Telmisartan induces an increase of eNOS activity in RBC resulting in an enhanced intravascular NO bioavailability, an ameliorated RBC deformability and a reduction of RBC and platelet aggregation. This could be a potential mechanism of the improvement of microcirculatory disorders, especially in patients with diabetes mellitus and arterial hypertension, treated with Telmisartan.
Timeline
- Start
- 2007-12
- Primary completion
- 2009-01
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telmisartan | Other / unclassified | 20 mg | — |
| Subject | Telmisartan | Other / unclassified | 80 mg | — |